Ono Pharmaceutical Co. Ltd (MU:ON4) — Market Cap & Net Worth
Market Cap & Net Worth: Ono Pharmaceutical Co. Ltd (ON4)
Ono Pharmaceutical Co. Ltd (MU:ON4) has a market capitalization of $7.29 Billion (€6.24 Billion) as of April 17, 2026. Listed on the MU stock exchange, this Germany-based company holds position #2825 globally and #470 in its home market, demonstrating a -1.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ono Pharmaceutical Co. Ltd's stock price €13.27 by its total outstanding shares 469907657 (469.91 Million).
Ono Pharmaceutical Co. Ltd Market Cap History: 2015 to 2026
Ono Pharmaceutical Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $392.45 Trillion to $7.29 Billion (-1.43% CAGR).
Ono Pharmaceutical Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ono Pharmaceutical Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
Ono Pharmaceutical Co. Ltd's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.13x
Ono Pharmaceutical Co. Ltd's market cap is 0.13 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $7.76 Billion | $160.28 Billion | $24.98 Billion | 0.05x | 0.31x |
| 2017 | $10.16 Billion | $244.80 Billion | $55.79 Billion | 0.04x | 0.18x |
| 2018 | $9.16 Billion | $261.84 Billion | $50.28 Billion | 0.03x | 0.18x |
| 2019 | $10.69 Billion | $288.63 Billion | $51.54 Billion | 0.04x | 0.21x |
| 2020 | $12.86 Billion | $292.42 Billion | $59.70 Billion | 0.04x | 0.22x |
| 2021 | $11.54 Billion | $309.28 Billion | $75.42 Billion | 0.04x | 0.15x |
| 2022 | $11.43 Billion | $361.36 Billion | $80.52 Billion | 0.03x | 0.14x |
| 2023 | $8.79 Billion | $447.19 Billion | $112.72 Billion | 0.02x | 0.08x |
| 2024 | $5.33 Billion | $502.67 Billion | $127.98 Billion | 0.01x | 0.04x |
| 2025 | $6.37 Billion | $486.87 Billion | $50.05 Billion | 0.01x | 0.13x |
Competitor Companies of ON4 by Market Capitalization
Companies near Ono Pharmaceutical Co. Ltd in the global market cap rankings as of April 17, 2026.
Key companies related to Ono Pharmaceutical Co. Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $809.09 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #19 globally with a market cap of $565.08 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #34 globally with a market cap of $369.53 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $310.79 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $809.09 Billion | $903.99 |
| #19 | Johnson & Johnson | NYSE:JNJ | $565.08 Billion | $234.54 |
| #34 | AbbVie Inc | NYSE:ABBV | $369.53 Billion | $208.99 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $310.79 Billion | $200.47 |
Ono Pharmaceutical Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Ono Pharmaceutical Co. Ltd's market cap moved from $392.45 Trillion to $ 7.29 Billion, with a yearly change of -1.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €7.29 Billion | +14.40% |
| 2025 | €6.37 Billion | +19.59% |
| 2024 | €5.33 Billion | -39.38% |
| 2023 | €8.79 Billion | -23.08% |
| 2022 | €11.43 Billion | -0.95% |
| 2021 | €11.54 Billion | -10.26% |
| 2020 | €12.86 Billion | +20.22% |
| 2019 | €10.69 Billion | +16.70% |
| 2018 | €9.16 Billion | -9.79% |
| 2017 | €10.16 Billion | +30.85% |
| 2016 | €7.76 Billion | -100.00% |
| 2015 | €392.45 Trillion | -- |
End of Day Market Cap According to Different Sources
On Apr 17th, 2026 the market cap of Ono Pharmaceutical Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.29 Billion USD |
| MoneyControl | $7.29 Billion USD |
| MarketWatch | $7.29 Billion USD |
| marketcap.company | $7.29 Billion USD |
| Reuters | $7.29 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules f… Read more